[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stage-iiib-lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stage-iiib-lung-cancer":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100604740",false,"NCT07153445","Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)","Phase II Clinical Trial of Chemotherapy + Atezolizumab for Stage IIIa and IIIb Non-small Cell Lung Cancer Followed by Atezolizumab as Adjuvant Treatment After Surgery and Atezolizumab as Maintenance Treatment for Non-resected Patients After Chemoradiotherapy","ATHENEA","Inclusion Criteria:\n\n* Previously untreated patients with histologically- or cytologically- documented Non Small-Cell Lung Cancer (NSCLC) who present stage IIIA - IIIB disease (according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology)\n* Confirm the absence of distant disease\n* ECOG (Performance status) 0-1\n* Adequate hematologic and organ function\n* All patients are notified of the investigational nature of this study and signed a written in-formed consent in accordance with institutional and national guidelines, including the Declaration of Helsinki prior to any trial-related intervention\n* Adequate lung function\n* Patients aged \\> 18 years\n* For female patients of childbearing potential, agreement (by patient and\u002For partner) to use a highly effective form(s) of contraception\n* For male patients with female partners of childbearing potential, agreement (by patient and\u002For partner) to use a highly effective form of contraception\n* Oral contraception should always be combined with an additional contraceptive method\n* Women who are not postmenopausal or surgically sterile must have a negative serum pregnancy test result within 8 days prior to initiation of study drug.\n* Patient capable of proper therapeutic compliance and accessible for correct follow-up\n\nExclusion Criteria:\n\n* Patients mutation or an amplification in the EGFRgene, ALK fusion oncogene.\n* Known STK-11 ligand alterations, MDM2 amplifications or ROS1 translocations.\n* Weight loss \\>10% within the previous 3 months.\n* Patients that receive previous treatment with antineoplasic drugs, chest radiotherapy, or previous surgery for lung cancer.\n* Malignancies other than Non Small-Cell Lung Cancer (NSCLC) within 3 years prior to enrolment\n* Pleural or pericardial effusion\n* Known hypersensitivity or allergy to atezolizumab formulation.\n* History of autoimmune disease or lung disease\n* Positive test for human immunodeficiency viruses (HIV)\n* Patients with active hepatitis B or hepatitis C or psitive for hepatitis C virus.\n* Active tuberculosis.\n* Symptomatic neuropathy grade \\> 1 according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0\n* Severe infections within 4 weeks prior to be included in the study","ALL","18 Years",{"count":19,"type":20},97,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is an open-label, phase II, multi-centre clinical trial. 97 Patients with stage IIIA and IIIB non-small cell lung cancer will be enrolled.\n\nThe treatment is Atezolizumab + Paclitaxel + Carboplatin 3 cycles as neoadjuvant\u002Finduction treatment. After the induction treatment every patient will be evaluated by a multidisciplinary team in each participant hospital to decide if the patient is candidate for surgery or not.\n\nDepending on the decision each patient will be treated in a different way. The primary objective is to evaluate the Progression free survival (PFS). The total trial duration will be 10 years approximately. Patient accrual is expected to be completed within 2 years. Two years of treatment, 5 years of follow up, and 4-6 months of close-out.",[26,27,28],"Non Small Cell Lung Cancer","Stage IIIA Lung Cancer","Stage IIIB Lung Cancer",[30,31,32,33],"Non small cell lung cancer","Atezolizumab","Non-resected lung cancer","Adjuvant treatment","RECRUITING","2025-11-17",{"date":37,"type":38},"2025-11-19","ACTUAL",{"date":40,"type":38},"2025-07-08",{"date":42,"type":20},"2035-05-02",{"name":44,"class":45},"Fundación GECP","OTHER",21,""]